Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
HKSE:06609's Days Payable is ranked worse than 61.71% of 794
companies
in the Medical Devices & Instruments industry
Industry Median: 68.505
vs HKSE:06609: 55.44
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Shanghai HeartCare Medical Technology Days Payable Chart
HKSE:06609 vs ABT, SYK, MDT: Days Payable Comparison
For the Medical Devices subindustry, Shanghai HeartCare Medical Technology's Days Payable, along with its competitors' market caps and Days Payable data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Shanghai HeartCare Medical Technology Days Payable vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Shanghai HeartCare Medical Technology's Days Payable distribution charts can be found below:
* The bar in red indicates where Shanghai HeartCare Medical Technology's Days Payable falls into.
Shanghai HeartCare Medical Technology Days Payable Calculation
Days Payable indicates the number of days that the account payable relative to cost of goods sold the company has. An increase of Days Payable may suggest that the company delays paying its suppliers.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Shanghai HeartCare Medical Technology (HKSE:06609) has a Days Payable of 57.16 as of Dec. 2025. Days payable represents the average amount of days a company waits to pay its invoices from suppliers. View historical data on Shanghai HeartCare Medical Technology and its competitors. This is 135% above median its historical median of 24.28. Over the past decade, Shanghai HeartCare Medical Technology's Days Payable has ranged from 15.01 to 61.33. According to the industry distribution chart, Shanghai HeartCare Medical Technology ranks #490 out of 794 companies in the Medical Devices & Instruments industry, placing it in the top 61.7%.
Is Shanghai HeartCare Medical Technology's Days Payable too high?
Shanghai HeartCare Medical Technology's current Days Payable of 57.16 is 135% above median its 10-year median of 24.28. Over the past 10 years, this metric has ranged from a low of 15.01 to a high of 61.33. The Medical Devices & Instruments industry median Days Payable is 68.51. Shanghai HeartCare Medical Technology's value of 57.16 is 16.6% below this industry median. Based on the distribution chart, Shanghai HeartCare Medical Technology ranks #490 out of 794 companies in the Medical Devices & Instruments industry, which is below the industry midpoint. Overall, Shanghai HeartCare Medical Technology has a GF Score™ of 78/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Shanghai HeartCare Medical Technology's Days Payable compare to ABT and SYK?
According to the Medical Devices & Instruments industry distribution chart, Shanghai HeartCare Medical Technology ranks #490 out of 794 companies for Days Payable. This places Shanghai HeartCare Medical Technology in the lower half of its industry. The industry median Days Payable is 68.51. Shanghai HeartCare Medical Technology's value of 57.16 is 16.6% below this benchmark. Historically, Shanghai HeartCare Medical Technology's own Days Payable has ranged from 15.01 to 61.33 over the past decade. While the company's 10-year median is 24.28 vs. the industry median of 68.51, Shanghai HeartCare Medical Technology has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Days Payable for a Medical Devices & Instruments company?
The median Days Payable among Medical Devices & Instruments companies is 68.51, based on 794 companies in the industry. Companies in the top quartile (top 25%) have a Days Payable significantly above this median, while those in the bottom quartile fall well below. However, Days Payable should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Shanghai HeartCare Medical Technology's current Days Payable of 57.16 is 16.6% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Days Payable mean?
A high Days Payable can signal that a stock is expensive relative to its fundamentals. Days payable represents the average amount of days a company waits to pay its invoices from suppliers. View historical data on Shanghai HeartCare Medical Technology and its competitors. For the Medical Devices & Instruments industry, the median Days Payable is 68.51 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Shanghai HeartCare Medical Technology's current Days Payable is 57.16, which is 135% above median its own 10-year median of 24.28. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Shanghai HeartCare Medical Technology stock overvalued right now?
Based on GuruFocus' analysis, Shanghai HeartCare Medical Technology (HKSE:06609) is currently considered Modestly Undervalued. The stock's GF Value™ is HK$54.80, compared to a current price of HK$48.24 — trading 12% below its estimated fair value. The current Days Payable is 57.16, which is 135% above median its 10-year median of 24.28 and 16.6% below the Medical Devices & Instruments industry median of 68.51. Shanghai HeartCare Medical Technology's overall GF Score™ is 78/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Days Payable calculated?
Days Payable is calculated from a company's financial statements. For Shanghai HeartCare Medical Technology (HKSE:06609), the current Days Payable is 57.16 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Shanghai HeartCare Medical Technology (HKSE:06609) Overvalued in 2026?
Based on GuruFocus' analysis, Shanghai HeartCare Medical Technology stock appears to be undervalued.
The current stock price of HK$48.24 is trading 12% below its estimated GF Value™ of HK$54.80.
GuruFocus considers Shanghai HeartCare Medical Technology to be Modestly Undervalued.
Key valuation signals for HKSE:06609:
Days Payable: 57.16 (135% above median its 10-year median of 24.28)
GF Value™: HK$54.80 vs. price of HK$48.24 (12% below fair value)
Industry Position: 16.6% below the Medical Devices & Instruments median (#490 of 794)
No single metric tells the full story. See the HKSE:06609 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Shanghai HeartCare Medical Technology Corp Ltd is an neuro-interventional medical device company. The company is committed to creating high-quality products for the prevention and treatment of stroke. The company focuses on Research and development, manufacturing and commercialization to fulfill the unmet needs of clinicians and patients to redefine the standard of care, reduce mortality rate, and improve prognosis by continuously launching new medical devices. Geographically, the Group's majority revenue is derived from Chinese Mainland.
78GF Score
Get the complete analysis for HKSE:06609
Days Payable is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
HKSE:06609 has been successfully added to your 
